Subodh Kumar1, Anuj Kumar Pathak2, Dibyajyoti Saikia3, Amish Kumar4. 1. Assistant Professor, Department of Pharmacology, SRMSIMS , Bareilly, UP, India . 2. Senior Resident, Department of Pharmacology, IGIMS , Patna, India . 3. Junior Resident, Department of Pharmacology, AIIMS , New Delhi, India . 4. Professor, Department of Medicine, SRMSIMS , Bareilly, UP, India .
Abstract
INTRODUCTION: Metformin is a preferred drug for starting treatment in type 2 diabetes mellitus. But, eventually most of the patients need additional drug to control blood sugar level. The choice of drug depends upon several factors including patient specific criteria, economical factors and treatment satisfaction. AIM: The aim of the present study is to investigate the effects of adding sitagliptin or glimepiride on efficacy, safety and treatment satisfaction in patients with type 2 diabetes mellitus. MATERIALS AND METHODS: It was a retrospective observational study on 50 patients each in sitagliptin and glimepiride group, who are receiving treatment for at least 12 weeks and are stable on respective treatment regimen. Glycated haemoglobin (HBA1c) was the primary measure of efficacy. Safety was assessed by checking weight gain/loss, hypoglycaemia episodes and other laboratory investigations. Patient satisfaction was assessed by Diabetes Treatment Satisfaction Questionnaire. RESULTS: The HbA1c level after 12-24 weeks of treatment was not found to be significant compared to each other or from baseline. Compared to baseline fasting plasma glucose & postprandial plasma glucose were lower in glimepiride group. Sitagliptin was associated with less episodes of hypoglycaemia. Weight gain was associated with glimepiride but it was non-significant (p=0.08). Overall treatment satisfaction score were better for sitagliptin but were not statistically significant. CONCLUSION: The efficacy of sitagliptin was comparable. Sitagliptin had superior adverse effect profile with less chances of hypoglycaemia and weight gain. Questionnaire scores were higher for sitagliptin indicating better treatment satisfaction compared to glimepiride.
INTRODUCTION:Metformin is a preferred drug for starting treatment in type 2 diabetes mellitus. But, eventually most of the patients need additional drug to control blood sugar level. The choice of drug depends upon several factors including patient specific criteria, economical factors and treatment satisfaction. AIM: The aim of the present study is to investigate the effects of adding sitagliptin or glimepiride on efficacy, safety and treatment satisfaction in patients with type 2 diabetes mellitus. MATERIALS AND METHODS: It was a retrospective observational study on 50 patients each in sitagliptin and glimepiride group, who are receiving treatment for at least 12 weeks and are stable on respective treatment regimen. Glycated haemoglobin (HBA1c) was the primary measure of efficacy. Safety was assessed by checking weight gain/loss, hypoglycaemia episodes and other laboratory investigations. Patient satisfaction was assessed by Diabetes Treatment Satisfaction Questionnaire. RESULTS: The HbA1c level after 12-24 weeks of treatment was not found to be significant compared to each other or from baseline. Compared to baseline fasting plasma glucose & postprandial plasma glucose were lower in glimepiride group. Sitagliptin was associated with less episodes of hypoglycaemia. Weight gain was associated with glimepiride but it was non-significant (p=0.08). Overall treatment satisfaction score were better for sitagliptin but were not statistically significant. CONCLUSION: The efficacy of sitagliptin was comparable. Sitagliptin had superior adverse effect profile with less chances of hypoglycaemia and weight gain. Questionnaire scores were higher for sitagliptin indicating better treatment satisfaction compared to glimepiride.
Entities:
Keywords:
Hyperglycaemia; Hypoglycaemia; Treatment satisfaction questionnaire; Weight gain
Authors: R Arechavaleta; T Seck; Y Chen; K J Krobot; E A O'Neill; L Duran; K D Kaufman; D Williams-Herman; B J Goldstein Journal: Diabetes Obes Metab Date: 2011-02 Impact factor: 6.577
Authors: Pablo Aschner; Mark S Kipnes; Jared K Lunceford; Matilde Sanchez; Carolyn Mickel; Debora E Williams-Herman Journal: Diabetes Care Date: 2006-12 Impact factor: 19.112
Authors: Debora Williams-Herman; Jeremy Johnson; Rujun Teng; Edmund Luo; Michael J Davies; Keith D Kaufman; Barry J Goldstein; John M Amatruda Journal: Curr Med Res Opin Date: 2009-03 Impact factor: 2.580
Authors: Silvio E Inzucchi; Richard M Bergenstal; John B Buse; Michaela Diamant; Ele Ferrannini; Michael Nauck; Anne L Peters; Apostolos Tsapas; Richard Wender; David R Matthews Journal: Diabetes Care Date: 2012-04-19 Impact factor: 19.112
Authors: T V Devarajan; S Venkataraman; Narayanan Kandasamy; Abraham Oomman; Hari Kishan Boorugu; S K P Karuppiah; Dushyant Balat Journal: Indian J Endocrinol Metab Date: 2017 Sep-Oct